摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-[4-(5,5-dimethyl-2-oxo-1,3-oxazolidin-3-yl)-2-fluorophenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one | 1238699-26-7

中文名称
——
中文别名
——
英文名称
1-[4-(5,5-dimethyl-2-oxo-1,3-oxazolidin-3-yl)-2-fluorophenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one
英文别名
3-[3-fluoro-4-[5-methoxy-4-oxo-3-(2-phenylpyrazol-3-yl)pyridazin-1-yl]phenyl]-5,5-dimethyl-1,3-oxazolidin-2-one
1-[4-(5,5-dimethyl-2-oxo-1,3-oxazolidin-3-yl)-2-fluorophenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one化学式
CAS
1238699-26-7
化学式
C25H22FN5O4
mdl
——
分子量
475.479
InChiKey
CCAYJZOYRIRGSJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4
  • 重原子数:
    35
  • 可旋转键数:
    5
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    89.3
  • 氢给体数:
    0
  • 氢受体数:
    8

反应信息

点击查看最新优质反应信息

文献信息

  • Pyridazinone compounds
    申请人:Taniguchi Takahiko
    公开号:US20100197651A1
    公开(公告)日:2010-08-05
    The present invention provides a compound which has the effect of PDE inhibition, and which is useful as a medicament for preventing or treating schizophrenia or so on. A compound of formula (I 0 ): wherein R 1 represents a substituent, R 2 represents a hydrogen atom, or a substituent, R 3 represents a hydrogen atom, or a substituent, Ring A represents an aromatic ring which can be substituted, and Ring B represents a 5-membered heteroaromatic ring which can be substituted, or a salt thereof.
    本发明提供了一种具有PDE抑制作用并且用作预防或治疗精神分裂症等病症的药物的化合物。该化合物的公式为(I0):其中,R1代表一个取代基,R2代表一个氢原子或一个取代基,R3代表一个氢原子或一个取代基,环A代表一个可被取代的芳香环,而环B代表一个可被取代的5元杂芳环,或其盐。
  • PYRIDAZINONE COMPOUNDS
    申请人:TANIGUCHI Takahiko
    公开号:US20120277204A1
    公开(公告)日:2012-11-01
    The present invention provides a compound which has the effect of PDE inhibition, and which is useful as a medicament for preventing or treating schizophrenia or so on. A compound of formula (I 0 ), wherein R1 represents a substituent; R2 represents a hydrogen atom, or a substituent; R3 represents a hydrogen atom, or a substituent; Ring A represents an aromatic ring which can be substituted, and Ring B represents a 5-membered heteroaromatic ring which can be substituted, or a salt thereof.
    本发明提供了一种具有PDE抑制作用的化合物,可用作预防或治疗精神分裂症等药物。化合物的式子为(I0),其中R1代表取代基;R2代表氢原子或取代基;R3代表氢原子或取代基;环A代表可取代的芳香环,环B代表可取代的五元杂环芳基环或其盐。
  • 1-phenyl-3-pyrazolylpyridazin-4(1H)-one compound
    申请人:Taniguchi Takahiko
    公开号:US08354411B2
    公开(公告)日:2013-01-15
    The present invention provides a compound which has the effect of PDE inhibition, and which is useful as a medicament for preventing or treating schizophrenia or so on. A compound of formula (I0), wherein R1 represents a substituent; R2 represents a hydrogen atom, or a substituent; R3 represents a hydrogen atom, or a substituent; Ring A represents an aromatic ring which can be substituted, and Ring B represents a 5-membered heteroaromatic ring which can be substituted, or a salt thereof.
    本发明提供了一种具有PDE抑制作用的化合物,可用作预防或治疗精神分裂症等药物。该化合物的化学式为(I0),其中R1代表取代基;R2代表氢原子或取代基;R3代表氢原子或取代基;环A代表可以被取代的芳香环,环B代表可以被取代的五元杂环芳香环,或其盐。
  • ALKYNE-, AZIDE- AND TRIAZOLE-CONTAINING FLAVONOIDS AS MODULATORS FOR MULTIDRUG RESISTANCE IN CANCERS
    申请人:The Hong Kong Polytechnic University
    公开号:US20150011513A1
    公开(公告)日:2015-01-08
    A triazole bridged flavonoid dimer compound library was efficiently constructed via the cycloaddition reaction of a series of flavonoid-containing azides (Az 1-15) and alkynes (Ac 1-17). These triazole bridged flavonoid dimers and their precursor alkyne- and azide-containing flavonoids were screened for their ability to modulate multidrug resistance (MDR) in P-gp-overexpressed cell line (LCC6MDR), MRP1-overexpressed cell line (2008/MRP1) and BCRP-overexpressed cell line (HEK293/R2 and MCF7-MX100). Generally, they displayed very promising MDR reversal activity against P-gp-, MRP1- and BCRP-mediated drug resistance. Moreover, they showed different levels of selectivity for various transporters. Overall, they can be divided into mono-selective, dual-selective and multi-selective modulators for the P-gp, MRP1 and BCRP transporters. The EC50 values for reversing paclitaxel resistance (141-340 nM) of LCC6MDR cells, DOX (78-590 nM) and vincristine (82-550 nM) resistance of 2008/MRP1 cells and topotecan resistance (0.9-135 nM) of HEK293/R2 and MCF7-MX100 cells were at nanomolar range. Importantly, a number of compounds displayed EC50 at or below 10 nM in BCRP-overexpressed cell lines, indicating that these bivalent triazoles more selectively inhibit BCRP transporter than the P-gp and MRP1 transporters. Most of the dimers are notably safe MDR chemosensitizers as indicated by their high therapeutic index values.
    通过一系列含有三唑桥联类黄酮二聚物的合成,使用环加成反应,利用一系列含有黄酮基团的叠氮化物(Az1-15)和炔烃(Ac1-17)构建了一个高效的化合物库。这些三唑桥联的类黄酮二聚体及其前体炔基和叠氮基类黄酮被筛选,以评估它们对过表达P-gp的细胞系(LCC6MDR)、MRP1过表达的细胞系(2008/MRP1)和BCRP过表达的细胞系(HEK293/R2和MCF7-MX100)调节多药耐药性(MDR)的能力。总体而言,它们展现了极具前景的P-gp、MRP1和BCRP介导的药物耐药性的MDR逆转活性。此外,它们显示出对各种转运体的不同程度的选择性。总体而言,它们可以分为单选择性、双选择性和多选择性的P-gp、MRP1和BCRP转运体调节剂。对于LCC6MDR细胞的紫杉醇耐药性(141-340 nM)、2008/MRP1细胞的DOX(78-590 nM)和长春新碱(82-550 nM)耐药性以及HEK293/R2和MCF7-MX100细胞的拓扑替康耐药性(0.9-135 nM),它们的EC50值处于纳摩尔范围。重要的是,许多化合物在BCRP过表达的细胞系中显示出EC50值在或低于10 nM,表明这些双价三唑更有选择性地抑制BCRP转运体而不是P-gp和MRP1转运体。大多数二聚体的治疗指数值非常高,表明它们是非常安全的MDR化疗敏感剂。
  • RADIOLABELED COMPOUNDS AND THEIR USE AS RADIOTRACERS FOR QUANTITATIVE IMAGING OF PHOSPHODIESTERASE (PDE10A) IN MAMMALS
    申请人:Taniguchi Takahiko
    公开号:US20140178304A1
    公开(公告)日:2014-06-26
    The present invention provides radiolabeled compounds useful as radiotracers for quantitative imaging of PDE10A in mammals. The compound of the present invention is represented by the formula (I): wherein each symbols are as defined in the specification.
    本发明提供了放射性标记化合物,用作哺乳动物中PDE10A的定量成像的放射性示踪剂。本发明的化合物由式(I)表示:其中每个符号如规范所定义。
查看更多